Search Jaypirca (type in keywords)
Search Medical Information
If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Jaypirca ® (pirtobrutinib) tablets
50 mg,100 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
VIDEO: What are the efficacy and safety results for pirtobrutinib in the CLL-321 study?
In a phase 3 CLL-321 study, pirtobrutinib showed improved PFS compared with IdelaR/BR and the most common TEAEs for patients who received pirtobrutinib were infections and neutropenia.
Date of Last Review: February 18, 2025
Document Number: VV-MED-169260
Are you satisfied with this content?